www.StockMarketFunding.com Dendreon Soars 40% Dendreon Reports Gains for Cancer Drug. DNDN closed up $3.02 or 39.74% to close at $10.62 on 48814260 shares vs the...
Biotech investing can be a cruel mistress, as best-in-class treatment status and momentum behind a stock can suddenly evaporate. As if Dendreon (Nasdaq: DNDN )...
Shares of Dendreon (NASDAQ:DNDN) are trading 9.5% higher Friday, up for the second consecutive session on optimism on sales of the firm's premier and only...
EquipNet has an exciting new project from Dendreon featuring lab and bioprocessing equipment. Some of the featured equipment from this Seattle, Washington facility includes: Cotter...
Aug. 4 (Bloomberg) -- Dendreon Corp., maker of the prostate-cancer drug Provenge, fell the most in two years after the company withdrew its 2011 revenue...
www.StockMarketFunding.com Dendreon Huge Drop Down 16.4% In After-Hours Commentary (VIDEO) Pt 1 DNDN Trading Video Dendreon Cancer Drug Dendreon DNDN Update Dendreon's Cancer Vaccine Provenge...
Regulators said that Dendreon Corp.'s (NASDAQ:DNDN) prostate cancer drug Provenge should be covered by the US government for use in older men, according to a...
